Nupercaine, the hydrochloride of α-butyl-oxycinchoninic acid-γ-diethylethylenediamide, has been used as a local anesthetic for the past nine years. Its use in ophthalmology was described in 1933 by Dillon and Greer1 and by Bochner.2 The latter used a 0.5 per cent solution containing epinephrine hydrochloride for instillation, and for infiltration a freshly prepared solution (1: 1,500) incorporating 10 drops of epinephrine hydrochloride for each 100 cc. The advantages claimed for nupercaine include prolonged anesthetic effect, relatively low toxicity and absence of effect on the corneal epithelium and on the intraocular pressure.
Toxic reactions have been reported after the employment of nupercaine in spinal anesthesia, and a few instances of dermatitis have been recorded from the use of an ointment containing nupercaine in the treatment of pruritus (Keyes and McLellan,3 Fowlkes,4 Fanburg,5 Hailey and Hailey6 and Cameron7).
Dr. Charles H. May and I have been
PERERA CA. OCULAR SENSITIVITY TO NUPERCAINE. Arch Ophthalmol. 1940;24(2):344–346. doi:10.1001/archopht.1940.00870020136012
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: